GSK receives FDA approval for expanded indication for FLUARIX(R) QUADRIVALENT (Influenza Vaccine) for persons 6 months and older

PHILADELPHIA, Jan. 12, 2018 -- (Healthcare Sales & Marketing Network) -- GSK [LSE/NYSE: GSK] announced today it has received approval from the US Food and Drug Administration's (FDA) Center for Biologics Evaluation and Research expanding the indication fo... Biopharmaceuticals, FDA GSK, FLUARIX QUADRIVALENT, Influenza Vaccine
Source: HSMN NewsFeed - Category: Pharmaceuticals Source Type: news